The role of Ischemia modified albumin in detecting diabetic nephropathy | ||
| SVU-International Journal of Medical Sciences | ||
| Article 37, Volume 6, Issue 1, January 2023, Pages 359-367 PDF (234.39 K) | ||
| Document Type: Original research articles | ||
| DOI: 10.21608/svuijm.2022.165289.1419 | ||
| Authors | ||
| Asmaa Ali Mahmoud Ahmed* 1; Eman Hassan Ali Salama2; Hassan Ahmed Hassanein Shehata1; Amal Khalifa Ahmed Noreldin1 | ||
| 1Department of Internal Medicine, Faculty of Medicine, Sohag University, Sohag 82524 , Egypt. | ||
| 2Department of Clinical Pathology, Faculty of Medicine, Sohag University, Sohag 82524,Egypt. | ||
| Abstract | ||
| Background: Ischemia-modified albumin (IMA) is considered a marker of oxidative stress and ischemia. Objectives: In this study, we aimed at establishing an association between IMA and diabetic nephropathy (DN) in type2 Diabetes mellitus (T2DM) patients. Patients and methods: One hundred individual participated in the study.70 T2DM patients, 35 in group A had DN, 35 in group B without DN and 30 healthy individuals, group C as a control group. We used urinary microalbuminuria test and urinary albumin creatinine ratio for assessment of diabetic nephropathy. Results: plasma levels of IMA were higher in T2DM with DN (122.47±7.23) u/ml than in T2DM without DN(79.60±7.76) u/mlwho were higher than the control group (41.79±1.54)u/ml, p 110.5 u/ml (sensitivity=100%, specificity=94.4%, PPV=87.9% NPP=100%). Conclusion: The ischemia modified albumin levels were significantly higher and positively associated with the duration of diabetes, RBS and HbA1c levels in T2DM patients with nephropathy. IMA could be used as a risk marker for Type 2 diabetic nephropathy. | ||
| Keywords | ||
| Ischemia modified albumin; Diabetes Mellitus; Random blood glucose; Diabetic nephropathy | ||
|
Statistics Article View: 399 PDF Download: 612 |
||
